AmbiJet: the world’s first and only highly effective plasma-based solution for Europe’s 16 Million periimplantitis patients urgently needing help to avoid losing their dental implantbroad
AmbiJet · Horizon Europe grant · 2022-10-01–2025-09-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
Regular dental check-ups and treatments not only ensure a beautiful smile, but good general health: a healthy oral cavity strengthens the immune system and acts as a barrier against various heart-, kidney-, or lungs-related diseases and diabetes. There is currently no effective solution to treat the 16.3 mn infected dental implants (EU, 2019). Freiburger Medizintechnik GmbH developed the solution dentists are looking for: a disruptive technology for highly effective infection control to fight periimplantitis. AmbiJet® is the world’s first and only plasma-based technology with the ability to kill bacteria on dental implants in-situ. It disrupts the status-quo of medical technologies by preventing the reinfection of disinfected surfaces and shows maximum effectiveness without side nor adverse effects: pharmacological and chemical substances are no longer required. AmbiJet® reduces inflammation, saves dental implants and helps patients live a healthier life.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| FREIBURGER MEDIZINTECHNIK GMBH | DE | coordinator | €1,389,062 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.